Seres Therapeutics, Inc. (MCRB)

Market Cap	54.81M -11.0%
Revenue (ttm)	1.15M
Net Income	-46.90M
EPS	-5.17
Shares Out	9.68M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	106,751
Open	6.28
Previous Close	6.32
Day's Range	5.63 - 6.40
52-Week Range	5.63 - 29.98
Beta	0.11
Analysts	Strong Buy
Price Target	22.00 (+288.69%)
Earnings Date	May 5, 2026

About MCRB

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 26, 2015
• Employees: 66
• Stock Exchange: NASDAQ
• Ticker Symbol: MCRB
• Website: https://www.serestherapeutics.com

Analyst Summary

According to one analyst, the rating for MCRB stock is "Strong Buy" and the 12-month stock price target is $22.0.

Price Target

$22.0

(288.69% upside)

Analyst Consensus: Strong Buy